세계의 리가아제 효소 시장 보고서(2025년)
Ligases Enzyme Global Market Report 2025
상품코드 : 1824404
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

리가아제 효소 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 12.0%를 나타내 56억 2,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 개인화된 의료 애플리케이션의 확대, 합성 생물학에 대한 관심 증가, 의약품 개발에서 리가아제 효소의 채택, 분자진단 수요 증가, 차세대 시퀀서에 리가아제의 통합으로 인한 것으로 예측됩니다. 예측 기간 동안의 주요 동향은 특정 용도에 특화된 리가아제의 개발, CRISPR 기반 기술에 리가아제 효소의 통합, 연구 및 진단을 위한 리가아제 기반 분석의 맞춤화, 리가아제 기반 등온 증폭 방법의 시작, 진단 분석에 대한 리가아제 연쇄반응(LCR)의 채용 등을 포함합니다.

향후 5년간의 성장률 12.0%라고 하는 예측은 전회의 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 핀란드와 싱가포르에서 개발된 DNA 리가아제 및 RNA 편집 효소의 가격을 상승시켜 유전 공학 프로젝트 지연과 핵심 시설 시약 비용 상승을 초래하여 미국의 분자 생물학 연구를 저해할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

암과 유전성 질환의 이환율 상승이 향후 수년간 리가아제 효소 시장 성장을 견인할 것으로 예측됩니다. 암은 비정상적인 세포의 무질서한 증식과 확산을 특징으로 하는 다양한 질병을 포함하는 반면, 유전성 질환은 개인의 유전 물질, 특히 DNA의 이상이나 돌연변이로 인한 다양한 병리를 포함합니다. 리가아제 효소는 DNA 복제, 수리 및 재조합에 중요한 역할을 합니다. 암의 경우, 리가아제는 손상된 DNA의 수복을 촉진하여 세포의 무질서한 증식의 원인이 됩니다. 게다가, 리가아제는 유전적 장애를 앓고 있는 세포를 표적으로 하고 배제하는 데 이용될 수도 있습니다. 예를 들어 2024년 7월 호주 보건복지연구소에서 발표한 보고서에 따르면 호주에서 진단된 암 환자수는 2022년 16만 570명에서 2023년 16만 4,694명으로 증가했습니다. 이 동향은 10만명당 403명의 신규암 환자와 144명의 암 관련 사망자라는 통계가 보여주듯 호주에서 암의 유병률 증가를 강조하는 것입니다. 게다가 등록자선단체 진피플 UK가 2023년 2월 발표한 보고서에 따르면 영국에서는 약 25명 중 1명의 어린이가 유전적 질환에 걸렸으며, 그 결과 240만명 이상이 유전적 질환을 안고 생활했습니다. 매년 약 3만 명의 아기와 어린이가 새롭게 진단됩니다. 이처럼 암과 유전성 질환의 유병률 증가가 리가아제 효소 시장 성장을 뒷받침하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Ligase enzymes, a class of proteins essential for facilitating the union of two DNA strands, play a pivotal role in biotechnology and pharmaceuticals. Their significance extends to various cellular processes, notably DNA replication and protein synthesis.

Key types of ligase enzyme products include E. coli DNA ligase, T4 DNA ligase, mammalian ligases, and thermostable ligases. E. coli DNA ligase specifically refers to an enzyme sourced from Escherichia coli (E. coli) bacteria. These ligases are derived from diverse organisms, including microorganisms, animals, and plants. They are integral to a multitude of techniques, encompassing ligase chain reaction (LCR), ligase detection reaction (LDR), next-generation sequencing (NGS), repeat expansion detection (RED), rolling circle amplification (RCA), proximity ligation assay (PLA), molecular cloning, ligation-mediated PCR, and mutation detection. These versatile applications cater to a broad spectrum of end-users, including research laboratories and institutions, pharmaceutical and biopharmaceutical companies, as well as diagnostic laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The ligases enzyme market research report is one of a series of new reports from The Business Research Company that provides ligases enzyme market statistics, including ligases enzyme industry global market size, regional shares, competitors with a ligases enzyme market share, detailed ligases enzyme market segments, market trends and opportunities, and any further data you may need to thrive in the ligases enzyme industry. This ligases enzyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ligases enzyme market size has grown rapidly in recent years. It will grow from $3.23 billion in 2024 to $3.57 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to the initial discovery and development of ligase enzymes, growth of the biotechnology industry, increased understanding of DNA repair mechanisms, expansion of genetic engineering applications, and rise in demand for molecular diagnostics.

The ligases enzyme market size is expected to see rapid growth in the next few years. It will grow to $5.62 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to the expansion of personalized medicine applications, growing focus on synthetic biology, adoption of ligase enzymes in drug development, increased demand for molecular diagnostics, and integration of ligases in next-generation sequencing. Major trends in the forecast period include the development of engineered ligases for specific applications, integration of ligase enzymes in CRISPR-based technologies, customization of ligase-based assays for research and diagnostics, rise of ligase-based isothermal amplification methods, adoption of ligase chain reaction (LCR) in diagnostic assays.

The forecast of 12.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. molecular biology research by inflating prices of DNA ligases and RNA editing enzymes developed in Finland and Singapore, resulting in delayed genetic engineering projects and higher core facility reagent costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of cancer and genetic disorders is anticipated to drive the growth of the ligase enzyme market in the coming years. Cancer encompasses a range of diseases marked by the uncontrolled proliferation and spread of abnormal cells, while genetic disorders involve various medical conditions caused by abnormalities or mutations in an individual's genetic material, particularly DNA. Ligase enzymes play a crucial role in DNA replication, repair, and recombination. In the context of cancer, ligases facilitate the repair of damaged DNA, which can contribute to the unchecked growth of cells. Additionally, ligases can be employed to target and eliminate cells affected by genetic disorders. For instance, a report from the Australian Institute of Health and Welfare in July 2024 indicated an increase in diagnosed cancer cases in Australia, from 160,570 in 2022 to 164,694 in 2023, showcasing a significant rise over the year. This trend underscores the growing prevalence of cancer in the nation, with statistics revealing 403 new cancer cases and 144 cancer-related deaths per 100,000 individuals. Furthermore, a February 2023 report by Gene People UK, a registered charity organization, stated that approximately 1 in 25 children in the UK are affected by a genetic condition, resulting in over 2.4 million individuals living with a genetic disorder. Annually, around 30,000 babies and children are newly diagnosed. Thus, the increasing prevalence of cancer and genetic disorders is propelling the growth of the ligase enzyme market.

An increase in research and development (R&D) activities is projected to drive the growth of the ligase enzyme market in the coming years. R&D encompasses the investigative efforts undertaken by companies or organizations to enhance existing products and processes or to create new ones. Ligase enzymes, commonly referred to as DNA ligases, are vital for joining DNA molecules together, making them indispensable tools for various R&D activities across multiple fields. For instance, a report from the Office for National Statistics in April 2024 revealed that the UK government's net expenditure on R&D (excluding contributions to the EU) rose to £15.5 billion ($19.375 billion) in 2022, reflecting a 10.5% increase from £14.0 billion ($17.5 billion) in 2021. Furthermore, in 2022, the total net expenditure on R&D, which included EU contributions and knowledge transfer activities, reached £16.4 billion ($20.5 billion), signifying an 8.9% increase from £15.0 billion ($18.75 billion) in 2021. Consequently, the rise in research and development activities is fueling the growth of the ligase enzyme market.

Major companies in the ligases enzyme market are advancing technologies like nanopore technologies to enhance the precision and efficiency of DNA sequencing and manipulation, thereby improving applications in genomics, synthetic biology, and personalized medicine. Nanopore technologies use nanopores to detect and analyze molecules, such as DNA or proteins, by measuring changes in ionic current as these molecules pass through the pore. For example, in February 2023, Eurofins Genomics, a US-based biotechnology firm, introduced the Express Oxford Nanopore Sequencing service. This service leverages Oxford Nanopore technology, enabling the sequencing of long DNA fragments. Such capabilities are especially advantageous for comprehensive genomic analyses, including metagenomics and structural variant detection.

Major companies in the ligases enzyme market are advancing technologies like the SAN HQ 2.0 enzyme to improve the efficiency and precision of nucleic acid manipulation in biomanufacturing processes. The SAN HQ 2.0 enzyme is specifically designed for biomanufacturing, effectively eliminating residual nucleic acids to enhance the purity and safety of processes such as viral vector production. For example, in December 2022, ArcticZymes Technologies ASA, a biotechnology firm based in Norway, launched the SAN HQ 2.0. This new product includes the SAN HQ 2.0 ELISA Kit, which represents a significant enhancement to ArcticZymes Technologies' portfolio. It demonstrates their commitment to providing reliable tools for quality control and compliance in biomanufacturing processes. This development not only addresses current industry demands but also positions ArcticZymes competitively in a market that prioritizes innovation and efficiency in bioprocessing.

In May 2022, QIAGEN N.V., a Germany-based provider of molecular testing solutions, acquired a majority stake in BLIRT S.A., a Poland-based biotechnology company known for manufacturing specialty ligase enzymes and reagents. This strategic acquisition is aimed at expanding QIAGEN's sample technology business by leveraging BLIRT's technology and expertise, thereby reinforcing QIAGEN's position in the life science industry. This strategic maneuver underscores the importance of inorganic growth strategies for gaining a competitive edge in the dynamic ligase enzyme market.

Major companies operating in the ligases enzyme market include BASF SE, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., GenScript, Promega Corporation, Oxford Nanopore Technologies Limited, Takara Bio Inc., New England Biolabs Inc., BioVision Inc., Enzo Life Sciences, Zymo Research, LGC Biosearch Technologies, Genetix Biotech Asia Pvt. Ltd., BLIRT S.A., Jena Bioscience, Bioline, Creative Enzymes, ArcticZymes Technologies ASA

North America was the largest region in the ligases enzyme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the ligases enzyme market report during the forecast period. The regions covered in the ligases enzyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ligases enzyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ligases enzyme market consists of sales of hi-t4 DNA ligase, splintR ligase, salt-t4 DNA ligase, t7 DNA ligase, quick ligation kits, Taq DNA ligase, and electroLigase. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ligases Enzyme Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ligases enzyme market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for ligases enzyme ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ligases enzyme market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Ligases Enzyme Market Characteristics

3. Ligases Enzyme Market Trends And Strategies

4. Ligases Enzyme Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Ligases Enzyme Growth Analysis And Strategic Analysis Framework

6. Ligases Enzyme Market Segmentation

7. Ligases Enzyme Market Regional And Country Analysis

8. Asia-Pacific Ligases Enzyme Market

9. China Ligases Enzyme Market

10. India Ligases Enzyme Market

11. Japan Ligases Enzyme Market

12. Australia Ligases Enzyme Market

13. Indonesia Ligases Enzyme Market

14. South Korea Ligases Enzyme Market

15. Western Europe Ligases Enzyme Market

16. UK Ligases Enzyme Market

17. Germany Ligases Enzyme Market

18. France Ligases Enzyme Market

19. Italy Ligases Enzyme Market

20. Spain Ligases Enzyme Market

21. Eastern Europe Ligases Enzyme Market

22. Russia Ligases Enzyme Market

23. North America Ligases Enzyme Market

24. USA Ligases Enzyme Market

25. Canada Ligases Enzyme Market

26. South America Ligases Enzyme Market

27. Brazil Ligases Enzyme Market

28. Middle East Ligases Enzyme Market

29. Africa Ligases Enzyme Market

30. Ligases Enzyme Market Competitive Landscape And Company Profiles

31. Ligases Enzyme Market Other Major And Innovative Companies

32. Global Ligases Enzyme Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ligases Enzyme Market

34. Recent Developments In The Ligases Enzyme Market

35. Ligases Enzyme Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기